Aharon Gefen

Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen

Rebecca Marsh, Marepalli B. Rao, Aharon Gefen et al. · Biology of Blood and Marrow Transplantation · 2015 · 72 citations · Full text

Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation “MSC-FFM”—Outcome Report of 92 Patients

Halvard Bönig, Zyrafete Kuçi, Selim Kuçi et al. · Cells · 2019 · 66 citations · Full text

Cell Therapy, Immunology, Immunotherapy +17

Xenopus Meis3 protein lies at a nexus downstream to Zic1 and Pax3 proteins, regulating multiple cell-fates during early nervous system development

Yoni Evgeni Gutkovich, Rachel Ofir, Yaniv M. Elkouby et al. · Developmental Biology · 2009 · 36 citations

Developmental Biology, Cell Division, Developmental Genetics +9

Serum Galactomannan Screening for Diagnosis of Invasive Pulmonary Aspergillosis in Children After Stem Cell Transplantation or with High-Risk Leukemia

Aharon Gefen, Irina Zaidman, Yael Shachor‐Meyouhas et al. · Pediatric Hematology and Oncology · 2015 · 19 citations

Prospective Evaluation of the Dosing Regimen of Vancomycin in Children of Different Weight Categories

Laila Nassar, Salim Hadad, Aharon Gefen et al. · Current Drug Safety · 2012 · 18 citations